Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 239

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 239
---
 $— $(10,970)$60,337 (1)The $1.6 million of contract asset is derived from our agreement with the DoD.(2)The Clover contract asset was included in non-current assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product.  During the three months ended March 31, 2025, we recorded an allowance for doubtful accounts of approximately $11.0 million relating to the contract asset recognized for Clover. See Note 6 for further discussion.

10. Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of our common stock outstanding.For the calculation of diluted net income per share, net income attributable to common stockholders for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans and change in fair value of warrant liability. Diluted net income per share attributable to common stockholders is computed by dividing the resulting net income attributable to common stockholders by the weighted-average number of fully diluted common shares outstanding.The numerators and denominators of the basic net loss and diluted net income per share computations for our common stock are calculated as follows (in thousands): Three Months EndedMarch 31, 20252024NumeratorNet loss attributable to common stockholders, basic and diluted$(96,099)$(8,721)  DenominatorWeighted average common stock outstanding, basic and diluted124,871 130,200 Net loss per share attributable to common stockholdersBasic$(0.77)$(0.07)Diluted$(0.77)$(0.07)The following were excluded from the calculation of diluted net loss per share as the effect of their inclusion would have been anti-dilutive (in thousands). Three months ended March 31, 20252024Outstanding securities not included in diluted net loss per share calculation:Stock options and stock awards18,77018,161Convertible Notes (as converted to common stock)16,19521,543Total34,96539,704

22

Table of Contents

11. Common Stock

Common Stock OutstandingAs of March 31, 2025, there were 123,696,958 shares of our common stock outstanding. As of March 31, 2025, we had $120.0 million remaining under the at-the-market Sales Agreement (the "ATM Agreement